Hikma Expects Generics To Hit A High In 2021
Announces Finasteride License From Almirall As Latest In A Series Of Deals
Hikma expects its generics business to hit the top end of its guidance for 2021, after recent launches and an improved product mix drove up its sales and operating margin. Meanwhile, the firm has announced a licensing agreement with Almirall for its Finjuve finasteride brand as the latest in a series of deals.
You may also be interested in...
Hikma has made the next move to build up its nascent US biosimilars business by striking a deal with Gedeon Richter for its denosumab candidate.
Hikma has agreed to acquire US sterile injectables specialist Custopharm in a deal that includes a $375m upfront purchase price and a further $50m in milestone payments. The transaction is set to bolster Hikma’s near-$1bn injectables business that currently accounts for around two-fifths of turnover.
Hikma told Generics Bulletin earlier this year it was reevaluating the US biosimilars market after witnessing successful launches from several of its rivals. Now the London-based firm has signed an agreement in the US to license and commercialize Bio-Thera Solutions’ Stelara biosimilar candidate.